Improvements in symptom severity and daily living with safinamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

被引：1
|
作者：
Szasz, J. [1 ]
Borgohain, R. [2 ]
Bhatt, M. [3 ]
Rossetti, S. [4 ]
Lucini, V. [4 ]
Anand, R. [5 ]
机构：
[1] Emergency Cty Hosp Targu Mures, Targu Mures, Romania
[2] Nizams Inst Med Sci, Hyderabad, India
[3] Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Mumbai, Maharashtra, India
[4] Newron Pharmaceut SpA, Bresso, Italy
[5] APC AG, St Moritz, Switzerland
来源：
PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷
关键词：
D O I：
10.1016/S1353-8020(09)70459-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.108
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [31] Comparison of desipramine and citalopram treatments for depression in Parkinson's disease:: A double-blind, randomized, placebo-controlled study
    Devos, David
    Dujardin, Kathy
    Poirot, Isabelle
    Moreau, Caroline
    Cottencin, Olivier
    Thomas, Pierre
    Destee, Alain
    Regis, Bordet
    Defebvre, Luc
    MOVEMENT DISORDERS, 2008, 23 (06) : 850 - 857
  • [32] A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in the Treatment of Men with Parkinson's Disease and Erectile Dysfunction
    Bernard, Bryan
    Metman, Leonard Verhagen
    Levine, Laurence
    Ouyang, Bichun
    Leurgans, Sue
    Goetz, Christopher
    NEUROLOGY, 2011, 76 (09) : A486 - A486
  • [33] A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease
    Wermuth, L
    EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (03) : 235 - 242
  • [34] Disease activity and quality-of-life improvements in patients with Behcet's syndrome: a phase III randomized, placebo-controlled, double-blind study of apremilast (RELIEF)
    Hatemi, G.
    Mahr, A.
    Ishigatsubo, Y.
    Song, Y. W.
    Melikoglu, M.
    Cheng, S.
    Mccue, S.
    Paris, M.
    Li, H.
    Yazici, Y.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : S155 - S155
  • [35] Opicapone OCEAN study in Parkinson's: design of a randomized double-blind placebo-controlled trial
    Chaudhuri, K. Ray
    Odin, P.
    Ferreira, J.
    Antonini, A.
    Rascol, O.
    Kurtis, M.
    Storch, A.
    Bannister, K.
    Costa, R.
    Magalhaes, D.
    Rocha, J. F.
    Soares-da-silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 902 - 902
  • [36] DHEA treatment of Alzheimer's disease - A randomized, double-blind, placebo-controlled study
    Wolkowitz, OM
    Kramer, JH
    Reus, VI
    Costa, MM
    Yaffe, K
    Walton, P
    Raskind, M
    Peskind, E
    Newhouse, P
    Sack, D
    De Souza, E
    Sadowsky, C
    Roberts, E
    NEUROLOGY, 2003, 60 (07) : 1071 - 1076
  • [37] Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease
    Suzuki, Masahiko
    Yoshioka, Masayuki
    Hashimoto, Masaya
    Murakami, Maiko
    Noya, Miki
    Takahashi, Daisuke
    Urashima, Mitsuyoshi
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2013, 97 (05): : 1004 - 1013
  • [38] Zishenpingchan granules for the treatment of Parkinson's disease:a randomized,double-blind,placebo-controlled clinical trial
    Qing Ye
    Xiao-Lei Yuan
    Can-Xing Yuan
    Hong-Zhi Zhang
    Xu-Ming Yang
    Neural Regeneration Research, 2018, (07) : 1269 - 1275
  • [39] The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study
    Yang, WH
    Drouin, MA
    Herbert, M
    Mao, Y
    Karsh, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (06) : 757 - 762
  • [40] Zishenpingchan granules for the treatment of Parkinson's disease: a randomized, double-blind, placebo-controlled clinical trial
    Ye, Qing
    Yuan, Xiao-Lei
    Yuan, Can-Xing
    Zhang, Hong-Zhi
    Yang, Xu-Ming
    NEURAL REGENERATION RESEARCH, 2018, 13 (07) : 1269 - 1275
12345